Zoe M. Weinstein, MD, MS

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Zoe M. Weinstein, MD, MS, is a graduate of Boston University’s Addiction Medicine Fellowship and board certified in Internal Medicine and Addiction Medicine. She has been the Director of Boston Medical Center’s interdisciplinary addiction consult service since July 2016. She has been NIDA grant funded as a co-investigator on multiple studies to deliver training and technical assistance to interdisciplinary provider teams (physicians, nurse practitioners, social workers, addiction counselors and recovery coaches) to expand treatment for opioid use disorder among hospitalized patients in New York City public hospitals as well as hospitals in Massachusetts as part of the HEALing Communities Study. She is currently site-PI of two NIDA Clinical Trial Network studies focused on inpatient addiction care. Her clinical and research work are also focused on long-term Office-Based Addiction Treatment (OBAT) with buprenorphine. She currently serves as Associate Director of Boston University’s Addiction Medicine Fellowship Program, a board member of AMERSA and is a site medical director of a local methadone clinic.

Publications

  • Published 11/24/2025

    Bradley KA, Hyun N, Idu A, Yu O, Bobb JF, Wartko PD, Weinstein Z, Matthews AG, McCormack J, Lee AK, Samet JH. Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial. Addiction. 2026 Mar; 121(3):629-642. PMID: 41287180.

    Read at: PubMed

  • Published 11/11/2025

    Weinstein ZM, Bratberg J, Joudrey PJ, Fiellin DA. Actions Needed for Pharmacy-Dispensed Methadone for Opioid Use Disorder in the United States. J Gen Intern Med. 2026 Mar; 41(4):1138-1141. PMID: 41217638.

    Read at: PubMed

  • Published 9/4/2025

    Weinstein ZM, Magane KM, Lodi S, Doeleman D, Ventura AS, Bazzi AR, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. Associations between COVID impact domains and time to buprenorphine treatment disengagement. Am J Drug Alcohol Abuse. 2025; 51(6):776-785. PMID: 40906491.

    Read at: PubMed

  • Published 8/28/2025

    Theisen J, Weinstein ZM, Davoust M, Ventura AS, Magane KM, Cheng A, Blakemore S, Blodgett J, Fielman S, Saitz R, Bazzi AR. Patient and Provider Perspectives on the Elimination of Urine Drug Testing in Office-Based Addiction Treatment. Subst Use Addctn J. 2026 Jan; 47(1):144-152. PMID: 40876939.

    Read at: PubMed

  • Published 3/4/2025

    Davoust M, Bazzi AR, Blakemore S, Blodgett J, Cheng A, Fielman S, Magane KM, Theisen J, Saitz R, Ventura AS, Weinstein ZM. Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study. Addict Sci Clin Pract. 2025 Mar 04; 20(1):21. PMID: 40033433.

    Read at: PubMed

View All 61 Publications:   View Full Profile in BUMC

Other Positions

  • Faculty, Medicine
    Boston University Chobanian & Avedisian School of Medicine

Websites

Education

  • University of California San Francisco, MD
  • Boston University School of Public Health, MS
  • Columbia University, BA

View all profiles